Kakeji Y, Ishikawa T, Suzuki S et al (2022) Registration Committee of the Japanese Gastric Cancer Association. A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013). Gastric Cancer 25:1082–1093

Article  PubMed  Google Scholar 

Nakao T, Kaneko R, Tanaka H et al (2021) Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan. Int J Clin Oncol 26:378–386

Article  CAS  PubMed  Google Scholar 

Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234–247

Article  CAS  PubMed  Google Scholar 

Kinoshita J, Fushida S, Tsukada T et al (2015) Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol 41:1354–1360

Article  CAS  PubMed  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N et al (2016) Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 19:329–338

Article  PubMed  Google Scholar 

Ito S, Oki E, Nakashima Y et al (2015) Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res 35:401–406

PubMed  Google Scholar 

Yamaguchi K, Yoshida K, Tanahashi T et al (2018) The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer 21:315–323

Article  CAS  PubMed  Google Scholar 

Arigami T, Matsushita D, Okubo K et al (2020) Clinical significance of conversion surgery for gastric cancer with peritoneal dissemination: a retrospective study. Oncology 98:798–806

Article  PubMed  Google Scholar 

Health NIO (2019) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v. 5, November 2017

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  CAS  PubMed  Google Scholar 

Fujitani K, Yang HK, Mizusawa J et al (2016) REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 17:309–318

Article  CAS  PubMed  Google Scholar 

Yamaguchi T, Takashima A, Nagashima K et al (2021) Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study. Gastric Cancer 24:701–709

Article  CAS  PubMed  Google Scholar 

Matsumoto R, Arigami T, Matsushita D et al (2020) Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol 18:179

Article  PubMed  PubMed Central  Google Scholar 

Toyota S, Naito H, Motoyoshi S et al (2020) Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer. Surg Case Rep 6:298

Article  PubMed  PubMed Central  Google Scholar 

Toyota S, Orita H, Fukuyama Y et al (2020) Successful Conversion surgery following chylous ascites after nivolumab for advanced gastric cancer. In Vivo 34:583–585

Article  PubMed  PubMed Central  Google Scholar 

Toyota Y, Okamoto K, Tanaka N et al (2021) Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab. Int Cancer Conf J 10:280–284

Article  PubMed  PubMed Central  Google Scholar 

Kumamoto T, Tomita T, Hojo Y et al (2021) Pathological complete response and successful conversion surgery after nivolumab therapy for stage IV oesophagogastric junction Cancer. In Vivo 35:2247–2251

Article  PubMed  PubMed Central  Google Scholar 

Watanabe H, Fujikawa H, Komori K et al (2021) Successful conversion surgery for stage iv gastric cancer after nivolumab monotherapy as third-line chemotherapy. Case Rep Gastroenterol 15:562–567

Article  PubMed  PubMed Central  Google Scholar 

Hidaka Y, Arigami T, Osako Y et al (2022) Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. World J Surg Oncol 20:193

Article  PubMed  PubMed Central  Google Scholar 

Ushimaru Y, Nishikawa K, Yasuhara Y et al (2021) Successful laparoscopic conversion surgery for gastric cancer with para-aortic lymph node metastasis after third-line chemotherapy: a case report. Int Cancer Conf J 11:50–56

Article  PubMed  PubMed Central  Google Scholar 

Noma T, Nishi M, Takasu C et al (2023) Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report. Int Cancer Conf J 13:11–16

Article  PubMed  PubMed Central  Google Scholar 

Mizuno K, Ito T, Ishigami M et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55:653–661

Article  CAS  PubMed  Google Scholar 

Andrade RJ, Aithal GP, Björnsson ES et al (2019) EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 70:1222–1261

Article  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, et al National Comprehensive Cancer Network. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714–1768

Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865–871

Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al ACTS-GC Group. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

Bang YJ, Kim YW, Yang HK, et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label randomised controlled trial. Lancet 379:315–321

Yoshida K, Kodera Y, Kochi M et al (2019) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 37:1296–1304

Article  CAS  PubMed  PubMed Central  Google Scholar